Currently, there are 699.44M common shares owned by the public and among those 697.28M shares have been available to trade.
The company’s stock has a 5-day price change of -0.04% and 6.03% over the past three months. DOC shares are trading 13.69% year to date (YTD), with the 12-month market performance up to 30.80% higher. It has a 12-month low price of $15.44 and touched a high of $23.26 over the same period. DOC has an average intraday trading volume of 4.95 million shares. The stock is trading above its simple moving averages at the SMA20, SMA50, and SMA200, as the current price level is off by 0.81%, 0.95%, and 12.80% respectively.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Institutional ownership of Healthpeak Properties Inc (NYSE: DOC) shares accounts for 93.56% of the company’s 699.44M shares outstanding.
It has a market capitalization of $16.06B and a beta (3y monthly) value of 1.13. The stock’s trailing 12-month PE ratio is 48.14, while the earnings-per-share (ttm) stands at $0.47. The company has a PEG of 9.65 and the debt-to-equity ratio at 1.06. Price movements for the stock have been influenced by the stock’s volatility, which stands at 2.54% over the week and 2.26% over the month.
Earnings per share for the fiscal year are expected to decrease by -38.60%, and -37.68% over the next financial year. EPS should grow at an annualized rate of 4.99% over the next five years, compared to -24.23% over the past 5-year period.
Looking at the support for the DOC, a number of firms have released research notes about the stock. Deutsche Bank stated their Buy rating for the stock in a research note on October 21, 2024, with the firm’s price target at $20-$28. Exane BNP Paribas was of a view on April 26, 2024 that the stock is Outperform, while Mizuho gave the stock Buy rating on April 22, 2024, issuing a price target of $22. BofA Securities on their part issued Buy rating on April 01, 2024.
